| Literature DB >> 35896992 |
Bright Chukwudi Orji1, Emily Bryce2, Bartholomew Odio3, Herbert Enyeribe Onuoha3, Elizabeth Njoku3, Charity Anoke3, Emmanuel Ugwa4, Joseph Enne3, Adetiloye Oniyire3, Emmanuel Otolorin2, Kayode Afolabi5, Nnenna C Ogbulafor6, Elizabeth Oliveras2.
Abstract
BACKGROUND: The World Health Organization recommends a minimum of three doses of quality-assured sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy (IPTp), in moderate to high malaria transmission areas in sub-Saharan Africa. Currently, coverage of IPTp lags behind coverage of antenatal care (ANC) visits; in Nigeria, 57% of women attended four or more ANC visits, whereas only 17% received the recommended three or more doses of IPTp. The innovative program aimed to close this gap by providing counseling on the benefits of comprehensive ANC, referral to ANC and community distribution of IPTp (C-IPTp), complementing IPTp at ANC. The study aimed to examine whether CHW referral to ANC improved the likelihood of receiving three or more doses of IPTp.Entities:
Keywords: Antenatal care; Community distribution; Intermittent preventive treatment; Malaria; Pregnancy
Mesh:
Substances:
Year: 2022 PMID: 35896992 PMCID: PMC9327266 DOI: 10.1186/s12884-022-04921-7
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.105
Participant characteristics (N = 936)
| Variable | N | % |
|---|---|---|
| 14 to 19 years | 64 | 6.84% |
| 20 to 24 years | 252 | 26.69% |
| 25 to 29 years | 327 | 34.94% |
| 30 to 34 years | 189 | 20.19% |
| 35 years or more | 104 | 11.11% |
| Nulliparous | 139 | 14.85% |
| Primiparous | 189 | 20.19% |
| Multiparous | 608 | 64.96% |
| No | 94 | 10.04% |
| Yes | 842 | 89.96% |
| First trimester | 260 | 27.78% |
| Second trimester | 546 | 58.33% |
| Third trimester (7th month) | 130 | 13.89% |
| No | 764 | 81.62% |
| Yes | 172 | 18.38% |
| No | 362 | 38.68% |
| Yes | 574 | 61.32% |
| No | 707 | 75.53% |
| Yes | 229 | 24.47% |
Fig. 1Distribution of the # of IPTp doses
Fig. 2Distribution of the # of referrals for ANC visits
Characteristics associated with IPTp3
| Variable | Did not receive IPTp3 ( | Received IPTp3 ( | Unadjusted Odds Ratio (OR) |
|---|---|---|---|
| N (%) | N (%) | OR (95% CI) | |
| No | 290 (80.1%) | 72 (19.9%) | REF |
| Yes | 417 (72.6%) | 157 (27.4%) | 1.52 (1.10–2.08)** |
| 14 to 19 years | 50 (78.1%) | 14 (21.9%) | REF |
| 20 to 24 years | 196 (77.8%) | 56 (22.2%) | 1.02 (0.53–1.98) |
| 25 to 29 years | 253 (77.4%) | 74 (22.6%) | 1.04 (0.55–1.99) |
| 30 to 34 years | 140 (74.1%) | 49 (25.9%) | 1.25 (0.64–2.46) |
| 35 years or more | 68 (65.4%) | 36 (34.6%) | 1.89 (0.92–3.87) |
| Nulliparous | 107 (77.0%) | 32 (23.0%) | REF |
| Primiparous | 134 (70.9%) | 55 (29.1%) | 1.37 (0.83–2.27) |
| Multiparous | 466 (76.6%) | 142 (23.4%) | 1.01 (0.66–1.58) |
| No | 79 (84.0%) | 15 (16.0%) | REF |
| Yes | 628 (74.6%) | 214 (25.4%) | 1.79 (1.01–3.18)* |
| First trimester | 201 (77.3%) | 59 (22.7%) | REF |
| Second trimester | 405 (74.2%) | 141 (25.8%) | 1.19 (0.84–1.68) |
| Third trimester (7th month) | 101 (77.7%) | 29 (22.3%) | 0.98 (0.59–1.62) |
*p < 0.05
**p < 0.01
Comparison of women who received IPTp doses versus those who never got IPTp
| Variable | One or more doses ( | Zero doses ( | |
|---|---|---|---|
| Mean (SD) | Mean (SD) | ||
| 2.4 (1.6) | 1.7 (1.1) | ||
| 0.7 (0.7) | 0.4 (0.5) | ||
| N (col %) | N (col %) | ||
| No | 262 (34.5%) | 100 (56.8%) | |
| Yes | 498 (65.5%) | 76 (43.2%) | |
| 14 to 19 years | 51 (6.7%) | 13 (7.4%) | 0.769 |
| 20 to 24 years | 200 (26.3%) | 52 (29.5%) | |
| 25 to 29 years | 264 (34.7%) | 63 (35.8%) | |
| 30 to 34 years | 158 (20.8%) | 31 (17.6%) | |
| 35 years or more | 87 (11.4%) | 17 (9.7%) | |
| 0.92 | |||
| Nulliparous | 112 (14.7%) | 27 (15.3%) | |
| Primiparous | 152 (20.0%) | 37 (21.0%) | |
| Multiparous | 496 (65.3%) | 112 (63.6%) | |
| No | 63 (8.3%) | 31 (17.6%) | |
| Yes | 697 (91.7%) | 145 (82.4%) | |
| First trimester | 181 (23.8%) | 79 (44.9%) | |
| Second trimester | 473 (62.2%) | 73 (41.5%) | |
| Third trimester (7th month) | 106 (13.9%) | 24 (13.6%) | |
| No | 604 (79.5%) | 160 (90.9%) | |
| Yes | 156 (20.5%) | 16 (9.1%) | |
Fig. 3Proportion of women receiving IPTp3, by facility
Multilevel logistic regression of characteristics associated with IPTp3
| Variable | Empty model | Full model |
|---|---|---|
| No | REF | |
| Yes | 1.60 (1.08–2.38)** | |
| 14 to 19 years | REF | |
| 20 to 24 years | 1.03 (0.50–2.11) | |
| 25 to 29 years | 1.27 (0.61–2.67) | |
| 30 to 34 years | 1.69 (0.76–3.72) | |
| 35 years or more | 2.35 (1.01–5.44)* | |
| Nulliparous | REF | |
| Primiparous | 1.26 (0.73–2.18) | |
| Multiparous | 0.75 (0.44–1.28) | |
| No | REF | |
| Yes | 1.51 (0.80–2.82) | |
| First trimester | REF | |
| Second trimester | 1.24 (0.86–1.80) | |
| Third trimester (7th month) | 1.10 (0.65–1.88) | |
| Variance (constant) | 0.554 (0.21–1.45) | 0.519 (0.20–1.38) |
| ICC | 0.144 (0.061–0.305) | 0.136 (0.06–0.30) |
| AIC | 1020.19 | 1018.53 |
| MOR | 2.03 | 1.99 |
*p < 0.05
**p < 0.01